Ensysce Biosciences Files 8-K for Bylaw Amendments & Financials
Ticker: ENSCW · Form: 8-K · Filed: Oct 18, 2024 · CIK: 1716947
| Field | Detail |
|---|---|
| Company | Ensysce Biosciences, INC. (ENSCW) |
| Form Type | 8-K |
| Filed Date | Oct 18, 2024 |
| Risk Level | low |
| Pages | 1 |
| Reading Time | 2 min |
| Key Dollar Amounts | $0.0001 |
| Sentiment | neutral |
Sentiment: neutral
Topics: corporate-governance, financials, filing
Related Tickers: ENS
TL;DR
Ensysce Bio (ENS) filed an 8-K for bylaw changes and financials. Keep an eye on updates.
AI Summary
Ensysce Biosciences, Inc. filed an 8-K on October 18, 2024, reporting amendments to its articles of incorporation or bylaws and financial statements. The company, formerly known as Leisure Acquisition Corp., is incorporated in Delaware and headquartered in La Jolla, California.
Why It Matters
This filing indicates corporate governance updates and the release of financial information, which are crucial for investors to assess the company's operational and legal standing.
Risk Assessment
Risk Level: low — This is a routine filing reporting corporate actions and financial statements, not indicating immediate operational or financial distress.
Key Players & Entities
- Ensysce Biosciences, Inc. (company) — Registrant
- Leisure Acquisition Corp. (company) — Former company name
- October 18, 2024 (date) — Date of report
- October 17, 2024 (date) — Date of earliest event reported
- Delaware (jurisdiction) — State of incorporation
- La Jolla, California (location) — Principal executive offices
FAQ
What specific amendments were made to Ensysce Biosciences' articles of incorporation or bylaws?
The filing indicates amendments were made, but the specific details of these amendments are not provided in the provided text excerpt.
What is the significance of filing financial statements as part of this 8-K?
Filing financial statements provides investors with an update on the company's financial performance and position as of the reporting date.
When was Ensysce Biosciences, Inc. formerly known as Leisure Acquisition Corp.?
The date of the name change from Leisure Acquisition Corp. to Ensysce Biosciences, Inc. was September 13, 2017.
What is the primary business of Ensysce Biosciences, Inc. according to its SIC code?
Ensysce Biosciences, Inc. is classified under Pharmaceutical Preparations (SIC code 2834).
What is the fiscal year end for Ensysce Biosciences, Inc.?
The fiscal year end for Ensysce Biosciences, Inc. is December 31.
Filing Stats: 429 words · 2 min read · ~1 pages · Grade level 11.2 · Accepted 2024-10-18 16:56:08
Key Financial Figures
- $0.0001 — ch registered Common Stock, par value $0.0001 per share ENSC The Nasdaq Stock Mar
Filing Documents
- form8-k.htm (8-K) — 38KB
- ex3-2b.htm (EX-3.2B) — 7KB
- 0001493152-24-041589.txt ( ) — 219KB
- ensc-20241018.xsd (EX-101.SCH) — 3KB
- ensc-20241018_lab.xml (EX-101.LAB) — 33KB
- ensc-20241018_pre.xml (EX-101.PRE) — 24KB
- form8-k_htm.xml (XML) — 4KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Dated: October 18, 2024 Ensysce Biosciences, Inc. By: /s/ Lynn Kirkpatrick Name: Dr. Lynn Kirkpatrick Title: President and Chief Executive Officer 3